Morgan E, Soerjomataram I, Rumgay H, Coleman HG, Thrift AP, Vignat J, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163(3):649-58.e2. https://doi.org/10.1053/j.gastro.2022.05.054.

Article  PubMed  Google Scholar 

Sheikh M, Roshandel G, McCormack V, Malekzadeh R. Current status and future prospects for esophageal cancer. Cancers (Basel). 2023;15(3). https://doi.org/10.3390/cancers15030765.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  CAS  PubMed  Google Scholar 

Uhlenhopp DJ, Then EO, Sunkara T, Gaduputi V. Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin J Gastroenterol. 2020;13(6):1010–21. https://doi.org/10.1007/s12328-020-01237-x.

Article  PubMed  Google Scholar 

Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev. 2010;19(6):1468–70. https://doi.org/10.1158/1055-9965.Epi-10-0012.

Article  PubMed  Google Scholar 

Islami F, DeSantis CE, Jemal A. Incidence trends of esophageal and gastric cancer subtypes by race, ethnicity, and age in the United States, 1997–2014. Clin Gastroenterol Hepatol. 2019;17(3):429–39. https://doi.org/10.1016/j.cgh.2018.05.044.

Article  PubMed  Google Scholar 

Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol. 2013;23(1):3–9. https://doi.org/10.1016/j.semradonc.2012.09.008.

Article  PubMed  PubMed Central  Google Scholar 

Ilson DH, van Hillegersberg R. Management of patients with adenocarcinoma or squamous cancer of the esophagus. Gastroenterology. 2018;154(2):437–51. https://doi.org/10.1053/j.gastro.2017.09.048.

Article  PubMed  Google Scholar 

Lander S, Lander E, Gibson MK. Esophageal cancer: overview, risk factors, and reasons for the rise. Curr Gastroenterol Rep. 2023;25(11):275–9. https://doi.org/10.1007/s11894-023-00899-0.

Article  PubMed  Google Scholar 

Alexandre L, Long E, Beales IL. Pathophysiological mechanisms linking obesity and esophageal adenocarcinoma. World J Gastrointest Pathophysiol. 2014;5(4):534–49. https://doi.org/10.4291/wjgp.v5.i4.534.

Article  PubMed  PubMed Central  Google Scholar 

Qin X, Jia G, Zhou X, Yang Z. Diet and esophageal cancer risk: an umbrella review of systematic reviews and meta-analyses of observational studies. Adv Nutr. 2022;13(6):2207–16. https://doi.org/10.1093/advances/nmac087.

Article  PubMed  PubMed Central  Google Scholar 

Alexandre L, Broughton T, Loke Y, Beales IL. Meta-analysis: risk of esophageal adenocarcinoma with medications which relax the lower esophageal sphincter. Dis Esophagus. 2012;25(6):535–44. https://doi.org/10.1111/j.1442-2050.2011.01285.x.

Article  CAS  PubMed  Google Scholar 

McColl KEL. What is causing the rising incidence of esophageal adenocarcinoma in the West and will it also happen in the East? J Gastroenterol. 2019;54(8):669–73. https://doi.org/10.1007/s00535-019-01593-7.

Article  PubMed  PubMed Central  Google Scholar 

Arnold M, Laversanne M, Brown LM, Devesa SS, Bray F. Predicting the future burden of esophageal cancer by histological subtype: international trends in incidence up to 2030. Am J Gastroenterol. 2017;112(8):1247–55. https://doi.org/10.1038/ajg.2017.155.

Article  PubMed  Google Scholar 

Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer. 1997;33(8):1216–20. https://doi.org/10.1016/s0959-8049(97)00088-9.

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7. https://doi.org/10.1200/jco.2006.06.8429.

Article  PubMed  Google Scholar 

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36–46. https://doi.org/10.1056/NEJMoa073149.

Article  CAS  PubMed  Google Scholar 

Al-Batran S-E, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol. 2008;26(9):1435–42. https://doi.org/10.1200/jco.2007.13.9378.

Article  CAS  PubMed  Google Scholar 

Mauer AM, Kraut EH, Krauss SA, Ansari RH, Kasza K, Szeto L, et al. Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol. 2005;16(8):1320–5. https://doi.org/10.1093/annonc/mdi249.

Article  CAS  PubMed  Google Scholar 

Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86(14):1086–91. https://doi.org/10.1093/jnci/86.14.1086.

Article  CAS  PubMed  Google Scholar 

Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J. 2000;6(5):316–23.

CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. https://doi.org/10.1016/S0140-6736(21)00797-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181–95. https://doi.org/10.1016/s1470-2045(23)00515-6.

Article  CAS  PubMed  Google Scholar 

Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. https://doi.org/10.1016/s0140-6736(21)01234-4.

Article  CAS  PubMed  Google Scholar 

Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, André T, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32(31):3520–6. https://doi.org/10.1200/jco.2013.54.1011.

Article  CAS  PubMed  Google Scholar 

El-Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol. 2004;15(6):960–5. https://doi.org/10.1093/annonc/mdh230.

Article  CAS  PubMed  Google Scholar 

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. https://doi.org/10.1200/jco.19.02105.

Article  CAS  PubMed  Google Scholar 

Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol. 2004;15(1):64–9. https://doi.org/10.1093/annonc/mdh007.

Article  CAS  PubMed